# V1 Empirics Check — deepseek/deepseek-v3.2 (Variant A)

**Model:** deepseek/deepseek-v3.2
**Variant:** A
**Date:** 2026-03-23T15:34:52.203997

---

**Review of "The Access Cost That Wasn't: WIC EBT Mandates, Vendor Exits, and Infant Health"**

**1. Idea Fidelity**
The paper deviates significantly from the original research plan outlined in the Idea Manifest, resulting in a less credible and less informative test of the proposed hypothesis.

*   **Identification Strategy:** The Manifest proposed three complementary strategies: 1) Staggered DiD (Callaway-Sant'Anna), 2) a Bartik-style IV exploiting pre-EBT vendor composition, and 3) a within-state analysis of Ohio's phased rollout. The paper executes only a pared-down version of Strategy 1. The critical Bartik IV—which was the core instrument for *vendor exits*—is absent. The paper instead uses EBT adoption as a direct treatment for health outcomes, implicitly assuming the *only* relevant channel is vendor exits and that the intensity of this first-stage shock is homogeneous. This is a major simplification that weakens the direct link to the "infrastructure access multiplier" mechanism.
*   **Data Source:** The Manifest specified the use of CDC Natality **microdata** (county or individual-level). The paper instead uses **aggregated** state-level Low Birth Weight (LBW) rates from the County Health Rankings. This aggregation loses crucial granularity, precludes heterogeneity analysis by individual characteristics (e.g., maternal education, race) or local market conditions, and introduces measurement error due to the use of multi-year averages. It fundamentally changes the scope and precision of the analysis.
*   **Research Question:** The question broadens from testing a specific mechanism ("Do vendor exits caused by EBT degrade infant health?") to a more general one ("Does EBT adoption affect infant health?"). While related, this shift muddles the contribution. The paper cannot convincingly attribute its null findings to the resilience of the vendor network, as it does not rigorously measure vendor exit variation or participant access costs.

**2. Summary**
This paper examines whether the state-level rollout of Electronic Benefit Transfer (EBT) in the WIC program, which prior work found caused independent vendor exits, adversely affected infant health as measured by low birth weight rates. Using state-year aggregated data and difference-in-differences designs, the paper finds precisely estimated null effects, suggesting the modernization did not cause measurable harm.

**3. Essential Points (Must Address for R&R)**
The following issues are critical and must be resolved for the paper to provide a credible answer to its motivating question.

**A. Invalid and Inconsistent Identification Strategy.** The empirical approach does not match the research question. The treatment variable (`EBT_{st}`) is an indicator for state-level EBT adoption. The hypothesized mechanism, however, is *not* EBT itself, but the *reduction in vendor access* caused by EBT. The paper lacks a **first-stage** analysis linking EBT adoption to *variation in vendor exits* across states (e.g., using the proposed Bartik instrument based on pre-existing vendor composition). Without this, the reduced-form estimates of EBT on health are difficult to interpret: a null result could mean (1) vendor exits didn't harm health, or (2) EBT did not cause meaningful exit variation in the sample, or (3) EBT had countervailing benefits that offset access costs. The current design cannot distinguish these. The authors must implement an instrumental variables (2SLS) strategy using EBT adoption interacted with a measure of state sensitivity to vendor exits (e.g., pre-EBT share of small independent vendors) as an instrument for a measure of vendor access (e.g., vendor density, participant travel distance).

**B. Aggregated Data Obscures Meaningful Variation and Introduces Bias.** Using pre-aggregated, state-level LBW rates from CHR is a severe limitation.
1.  **Measurement Error/Attenuation:** CHR rates are multi-year moving averages (e.g., the 2024 release uses 2019-2021 data). This poorly aligns with precise treatment timing, smears effects across periods, and very likely attenuates estimates toward zero. The authors' 2-year lag adjustment is ad hoc and does not solve the core problem.
2.  **Lost Heterogeneity:** The policy's impact likely varied by individual risk factors (e.g., poverty, rurality) and local market concentration. State-level aggregation averages away these potentially offsetting effects, which could mask significant local harms. The authors must use the **CDC Natality microdata** (as specified in the Manifest) at the county or individual level. This allows for direct alignment of birth dates with treatment timing, analysis of heterogeneous effects, and the use of finer-grained fixed effects.

**C. No Direct Evidence for the Proposed Mechanism or Its Absence.** The discussion speculates why vendor exits might not matter (e.g., "phantom vendors," substitution to chains) but provides **no empirical evidence**. For a paper centrally about infrastructure access, the absence of any analysis on WIC participation, vendor density, or shopping patterns is glaring. The authors should:
1.  Test the first stage: Replicate Meckel's (2020) finding on vendor exits with their data/period.
2.  Test the intermediate channel: Examine if EBT adoption (or instrumented vendor exits) affected county-level WIC participation rates (using FNS data).
3.  Test for heterogeneous effects by pre-treatment local vendor concentration (urban/rural, Herfindahl index of WIC vendors).

**4. Suggestions**
*   **Re-align with Original Design:** Refocus the paper on estimating the effect of **vendor exits** on health. The core specification should be a 2SLS model: `Health_{ist} = α + β * VendorAccess_{st} + γX_{ist} + δ_s + λ_t + ε_{ist}`, where `VendorAccess_{st}` is instrumented by `EBT_{st} * PreEBT_VendorFragmentation_s`. This directly tests the infrastructure hypothesis.
*   **Use Appropriate Data and Timing:**
    *   Obtain and use the **CDC Natality microdata** (restricted access via a DUA if necessary). Define the treatment timing for each birth based on the *in utero* exposure period (e.g., conception date). This is more biologically relevant than a state-year panel.
    *   If microdata remain unavailable, use **county-level** NCHS natality files (publicly available) and construct annual, not multi-year average, LBW rates. Carefully align the EBT effective date for each county (respecting Ohio's phased rollout as a robustness check).
*   **Strengthen the Difference-in-Differences Execution:**
    *   The TWFE model is correctly flagged as potentially biased. Fully embrace the Callaway-Sant'Anna estimator as the primary specification, not just a robustness check. Present event-study plots from this estimator to visually assess pre-trends and dynamic effects.
    *   The "state-specific linear trends" robustness check is too blunt and can over-control. It's better to use the ** Rambachan & Roth (2023) or Freyaldenhoven et al. (2023)** sensitivity analyses alongside the event-study plot to assess robustness to plausible violations of parallel trends.
*   **Expand Outcome Variables:** The Manifest listed preterm birth and breastfeeding initiation. Analyze these. A null effect on LBW is less surprising if the primary margin of effect is gestational age (preterm) or postnatal nutrition (breastfeeding). A package of related outcomes provides a more comprehensive test.
*   **Improve Interpretation and Context:**
    *   Discuss the **power** of the test. Given the small first-stage effect (5.4pp exit rate), what is the Minimum Detectable Effect (MDE) on LBW? The presented confidence intervals are informative, but a formal power calculation would help interpret the null.
    *   The discussion on "phantom vendors" is insightful but should be framed as a **testable hypothesis**. Can the authors find data (e.g., from USDA) on vendor redemption volumes pre-EBT to see if exiting vendors were low-volume?
    *   Engage more deeply with **Ambrozek et al. (2025)**. Their finding of "no redemption effect" is directly relevant. Does their data suggest high participant elasticity to vendor exit? This could be a key explanation for your null result.
*   **Presentation and Robustness:**
    *   `Table 2 (Robustness)` column (4) "Intensity" is misleading. A positive coefficient for "years exposed" is presented as a "small cumulative positive effect," but if the initial effect is zero, a positive trend likely reflects underlying secular trends unrelated to treatment. This should be reinterpreted or dropped.
    *   The abstract's conclusion that results "rul[e] out economically meaningful harm" is too strong given the data aggregation and identification issues. Temper this language to reflect the more limited claim that *state-average* LBW rates did not meaningfully change post-EBT.
    *   Consider a **bounding exercise** (e.g., Oster 2019) to quantify how severe selection on unobservables would need to be to explain away the null result.

**Overall:** The paper addresses a timely and policy-relevant question. In its current form, however, the empirical execution does not meet the standards for a credible causal analysis of the proposed mechanism. The authors have a strong blueprint in their original Idea Manifest. By returning to that design—implementing an IV strategy, using disaggregated health data, and directly testing the vendor access channel—they can produce a much more convincing and publishable study. I recommend a **major revision** contingent on successfully addressing these core issues.
